A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab; Doxorubicin
- Indications Sarcoma
- Focus Therapeutic Use
- 24 Jun 2013 Biomarkers information updated